What is the global market size of Next Generation Cancer Diagnostics Market?

Next Generation Cancer Diagnostics Market size was valued at USD 8.40 billion in 2021 and is poised to grow from USD 9.90 billion in 2022 to USD 31.15 billion by 2030, at a CAGR of 17.8% during the forecast period (2023-2030).

Who are the key vendors in the Global Next Generation Cancer Diagnostics Market?

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service. 'Abbott Laboratories', 'Agilent Technologies, Inc.', 'Bio-Rad Laboratories, Inc.', 'Danaher Corporation', 'Exact Sciences Corporation', 'F. Hoffmann-La Roche Ltd.', 'GE Healthcare', 'Grail, Inc.', 'Guardant Health, Inc.', 'Hologic, Inc.', 'Illumina, Inc.', 'Merck & Co., Inc.', 'Myriad Genetics, Inc.', 'NanoString Technologies, Inc.', 'Natera, Inc.', 'NeoGenomics, Inc.', 'Qiagen N.V.', 'Quest Diagnostics Incorporated', 'Siemens Healthineers AG', 'Sysmex Corporation', 'Thermo Fisher Scientific, Inc.', 'Veracyte, Inc.'.

Next Generation Cancer Diagnostics Market Size, Share, Growth Analysis, By Technology(Next-generation Sequencing, qPCR & Multiplexing, Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays), By Application(Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis), By Cancer Type(Lung, Breast, Colorectal, Cervical), By Function(Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2226 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 67 | Figures: 77

Next Generation Cancer Diagnostics Market Regional Insights

The largest market is expected to be in North America in 2023 and for the duration of the forecast. High per capita healthcare spending and supportive healthcare policies are responsible for the regional market expansion.

Asia Pacific is predicted to have the fastest growth rate in 2023 and will continue to do so throughout the projection period. The Asia Pacific region has experienced faster growth due to a number of variables, including a sizable untapped consumer base and recent technical advancements in healthcare research. During the projected period, it is also anticipated that significantly larger investments in healthcare research and the economic development of these regions will increase market potential.

Next Generation Cancer Diagnostics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Next Generation Cancer Diagnostics Market size was valued at USD 11.60 Billion in 2022 and is poised to grow from USD 13.66 Billion in 2023 to USD 43.02 Billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service. 'Abbott Laboratories (US) ', 'Agilent Technologies, Inc. (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Danaher Corporation (US) ', 'Exact Sciences Corporation (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'GE Healthcare (US) ', 'Guardant Health, Inc. (US) ', 'Hologic, Inc. (US) ', 'Illumina, Inc. (US) ', 'Merck & Co., Inc. (US) ', 'Myriad Genetics, Inc. (US) ', 'NanoString Technologies, Inc. (US) ', 'Natera, Inc. (US) ', 'NeoGenomics, Inc. (US) ', 'Qiagen N.V. (Netherlands) ', 'Quest Diagnostics Incorporated (US) ', 'Siemens Healthineers AG (Germany) ', 'Sysmex Corporation (Japan) ', 'Thermo Fisher Scientific, Inc. (US) ', 'Veracyte, Inc. (US)'

The rising demand for personalized medicines is another factor driving the growth of the next generation cancer diagnostics market. Personalized medicine involves tailoring treatments to individual patients based on their genetic profile and other characteristics. Next generation cancer diagnostics tools can help identify patients who are most likely to benefit from personalized treatments.

Liquid biopsy tests have emerged as a promising alternative to traditional tissue biopsy tests for cancer diagnosis and treatment monitoring. These tests involve the analysis of a patient's blood, urine, or other bodily fluids to detect cancer cells and other biomarkers. Liquid biopsy tests are less invasive and less expensive than traditional biopsy tests, and they can provide more frequent and accurate results. As a result, there has been a growing adoption of liquid biopsy tests in the market, with several companies investing in the development of these tests.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Next Generation Cancer Diagnostics Market Regional Insights

Next Generation Cancer Diagnostics Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Next Generation Cancer Diagnostics Market?

Who are the key vendors in the Next Generation Cancer Diagnostics Market?

What is the key driver of Next Generation Cancer Diagnostics Market?

What is the key market trend for Next Generation Cancer Diagnostics Market?

Which region accounted for the largest share in Next Generation Cancer Diagnostics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300